These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31901017)

  • 1. Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.
    Sakurai R; Kaira K; Miura Y; Sunaga N; Saito R; Oyama T; Hisada T; Yamada M
    Thorac Cancer; 2020 Feb; 11(2):426-435. PubMed ID: 31901017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
    Miura Y; Kaira K; Sakurai R; Sunaga N; Saito R; Hisada T; Yamada M
    Lung Cancer; 2018 Jan; 115():42-48. PubMed ID: 29290260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
    Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
    J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of amrubicin third-line chemotherapy in patients with relapsed extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute.
    Sonehara K; Tateishi K; Fukushima T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
    Thorac Cancer; 2019 Sep; 10(9):1805-1811. PubMed ID: 31350820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amrubicin for non-small-cell lung cancer and small-cell lung cancer.
    Kurata T; Okamoto I; Tamura K; Fukuoka M
    Invest New Drugs; 2007 Oct; 25(5):499-504. PubMed ID: 17628745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amrubicin for the treatment of advanced lung cancer.
    Kurata T
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):171-80. PubMed ID: 19239396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
    Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
    Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer.
    Igawa S; Sasaki J; Ishihara M; Otani S; Maki S; Hiyoshi Y; Kasajima M; Katono K; Takakura A; Masuda N
    Chemotherapy; 2013; 59(2):99-105. PubMed ID: 24021914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.
    Sawa T; Yana T; Takada M; Sugiura T; Kudoh S; Kamei T; Isobe T; Yamamoto H; Yokota S; Katakami N; Tohda Y; Kawakami A; Nakanishi Y; Ariyoshi Y
    Invest New Drugs; 2006 Mar; 24(2):151-8. PubMed ID: 16502350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy.
    Saigusa M; Asada K; Akamatsu T; Tanaka Y; Endo Y; Yamamoto A; Morita S; Shirai T
    Oncol Res Treat; 2019; 42(1-2):52-56. PubMed ID: 30537755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
    Nogami N; Hotta K; Segawa Y; Takigawa N; Hosokawa S; Oze I; Fujii M; Ichihara E; Shibayama T; Tada A; Hamada N; Uno M; Tamaoki A; Kuyama S; Ikeda G; Osawa M; Takata S; Tabata M; Tanimoto M; Kiura K
    Acta Oncol; 2012 Jul; 51(6):768-73. PubMed ID: 22283472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC.
    Imai H; Kaira K; Naruse I; Kasahara N; Kamide Y; Ono A; Masuda T; Sunaga N; Minato K; Hisada T
    Anticancer Res; 2020 Mar; 40(3):1571-1578. PubMed ID: 32132059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
    Igawa S; Otani S; Ryuge S; Fukui T; Nakahara Y; Hiyoshi Y; Ishihara M; Kusuhara S; Harada S; Mitsufuji H; Kubota M; Sasaki J; Masuda N
    Invest New Drugs; 2017 Oct; 35(5):642-648. PubMed ID: 28631097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-progression survival is strongly linked to overall survival in refractory small-cell lung cancer patients who received amrubicin.
    Imai H; Kaira K; Mori K; Watase N; Hisada T; Yamada M; Minato K
    J Cancer Res Ther; 2020; 16(4):764-770. PubMed ID: 32930116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
    Otani S; Hamada A; Sasaki J; Wada M; Yamamoto M; Ryuge S; Takakura A; Fukui T; Yokoba M; Mitsufuji H; Toyooka I; Maki S; Kimura M; Hayashi N; Ishihara M; Kasajima M; Hiyoshi Y; Katono K; Asakuma M; Igawa S; Kubota M; Katagiri M; Saito H; Masuda N
    Am J Clin Oncol; 2015 Aug; 38(4):405-10. PubMed ID: 26214085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.
    Harada T; Oizumi S; Ito K; Takamura K; Kikuchi E; Kuda T; Sugawara S; Suzuki A; Maemondo M; Fujita Y; Kinoshita I; Inoue A; Hommura F; Katsuura Y; Dosaka-Akita H; Isobe H; Nishimura M;
    Oncologist; 2013; 18(4):439-45. PubMed ID: 23442308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
    Guinee DG; Holden JA; Benfield JR; Woodward ML; Przygodzki RM; Fishback NF; Koss MN; Travis WD
    Cancer; 1996 Aug; 78(4):729-35. PubMed ID: 8756364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.